Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$33.17 +2.00%

+$0.69 today

Market cap
$6.86B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.91M

Average 1.84M

IMVT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Immunovant, Inc.NASDAQ: IMVT

Research & Development · Q2 FY2027 · quarter ended Sep 2026

Research & development dips below year-ago levels

Q2 FY2027 research & development of $85.01M fell 25.6% year over year, behind the +16.2% change in trailing-twelve-month research & development. Sequentially, it fell 40.4% from the prior quarter. Over 3 fiscal years it compounded at +41.8% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -25.6% toward the trailing-twelve-month pace of +16.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$85.01M-40.4% QoQ
Last fiscal yearMar 2026
$456.66M+26.5% YoY
LTMSep 2026
$468.85M+16.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.6%——
1 year+26.5%——
3-year CAGR+41.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2026
456.66M USD
Year-over-year change
+26.5%
4-year CAGR
+45.5%

Research & Development vs competitors

How IMVT compares with its peers on the latest reported figures

  • IMVT's LTM Sep 2026 research & development of $468.85M is the highest of the 11 companies compared; the peer median is $145.31M.
  • Its year-over-year change of +16.2% is the 7th highest of 11, against a peer median of +19.9%.
  • Research & development amounts to 6608.2% of revenue for IMVT, versus a peer median of 41.9%.
IMVT Competitors Peer median
Research & Development for IMVT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMVTImmunovant, Inc.LTM Sep 2026$468.85M +16.2%+41.8%6608.2%
ZBIOZenas BioPharma, Inc.LTM Mar 2026$360.26M +137.9%+38.9%—
TGTXTG Therapeutics, Inc.LTM Sep 2026$236.22M +65.3%+8.5%26.3%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$188.07M +22.3%+26.8%—
ANNXAnnexon, Inc.LTM Mar 2026$172.31M +17.5%+18.0%—
CABACabaletta Bio, Inc.LTM Mar 2026$151.01M +44.8%+53.7%—
TRAXFirst Tracks Biotherapeutics IncFY2025$139.61M -8.4%——
ANABAnaptysBio, Inc.LTM Mar 2026$128.65M -23.4%+15.3%55.4%
IMUXImmunic, Inc.LTM Mar 2026$86.08M +3.9%+4.8%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M +60.6%-12.2%677.9%
QTTBQ32 Bio Inc.LTM Mar 2026$15.25M -66.4%-18.8%28.4%
Peer median (excluding IMVT) $145.31M+19.9%+15.3%41.9%

Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development101.81M160.26M212.93M360.92M456.66M
Selling, General & Admin54.23M48.02M57.28M77.24M76.24M
Operating Expenses156.03M208.28M270.21M438.15M532.9M
Depreciation & Amortization126K193K231K377K409K
EBITDA(156.69M)(198.28M)(258.54M)(412.57M)(504.98M)
EBITDA Margin—————
Operating Income(156.03M)(208.28M)(270.21M)(438.15M)(532.9M)
Operating Margin—————
Interest Income07.58M24.95M24.73M25.33M
Interest Expense012.48M000
Other Income / Expenses(781K)(2.68M)11.44M25.2M27.51M
Income Before Tax(156.81M)(210.95M)(258.77M)(412.95M)(505.39M)
Pre-Tax Margin—————
Income Tax Expense(84K)9K567K891K215K
Net Income(156.73M)(210.96M)(259.34M)(413.84M)(505.61M)
Net Margin—————
EPS (Basic)(1.43)(1.71)(1.88)(2.73)(2.77)
EPS (Diluted)(1.43)(1.71)(1.88)(2.73)(2.77)
Weighted Avg Shares109.68M123.08M138.1M151.57M182.42M
Weighted Avg Shares (Diluted)109.68M123.08M138.1M151.57M182.42M

Immunovant, Inc.

NASDAQ:IMVT

Intrinsic Alpha fair value

Locked

Current Price

$33.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.